| Release Date: January 2008 | Valid Through: December 31, 2008 |
Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)TM
|
| Fee: There is no fee for this activity. |
| Target Audience: This CME activity is designed for oncology/hematology professionals who treat patients with myelodysplastic syndromes (MDS). |
This CME activity is based on the following:
Updates in the Management of Myelodysplastic Syndromes: A Report from the 2007 American Society of Hematology (ASH) Meeting
Mikkael A. Sekeres, MD, MS, Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio
Please read the following CME information for this activity and then select the link below to launch the activity.
Mikkael Sekeres, MD, MS
Dr. Mikkael A. Sekeres is Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine and staff in the Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, in Ohio. He earned a medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr. Sekeres completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospitaland a fellowship in hematology-oncology at the Dana-Farber Cancer Institute in Boston. He is vice-chair of the medical advisory board of the Aplastic Anemia and Myelodysplastic Syndrome (MDS) International Foundation as well as on the scientific review committee. His current research focuses on patients with MDS and older adults with acute myeloid leukemia.
Learning Objectives
In general, oncology/hematology professionals who avail themselves of the conference summary on MDS should be able to:
- Understand the clinical impact of emerging therapies and supportive care strategies.
- Evaluate the published data based on study design, the reported results, and authors’ conclusions.
- Consider the reviewed data as it relates to previous, concurrent and the future practice of clinical oncology.
Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Creative Educational Concepts, Inc. (CEC) and OncoEd, Inc. CEC is accredited by the ACCME to provide continuing medical education for physicians. CEC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. CEC is an equal opportunity/affirmative action institution. | Instructions for Participation This activity was released January 2008 and will be valid through December 31, 2008. There are no fees for participating and receiving credit for this activity. To successfully complete this activity, participants must do the following: - Read the target audience, learning objectives, and author disclosures.
- Study the educational activity online or printed out.
- Read, complete, and submit answers to the post test questions and evaluation questions online and click "submit" when finished.
- After clicking "submit," your online certificate will be made available for you to view and print.
Hardware/Software Requirements This website requires version 4.x browsers or higher from Microsoft or Netscape. It has been optimized for Microsoft Browsers. |
Supporters
This activity is supported by an educational donation provided by Amgen.
Faculty and Disclosures
CEC is committed to the provision of CME that is balanced, objective, and evidence based. CEC adheres to Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards. Accordingly, all parties involved in content development have disclosed any real or apparent conflicts of interest relating to the topics of this educational activity and the disclosure summary follows. CEC has established mechanisms to resolve conflicts of interest should they arise. Participants in CEC CME programs are afforded the opportunity to provide feedback on the quality of individual programs.
Author: Mikkael Sekeres, MD, MS
Disclosure: Dr. Sekeres has disclosed that he has consulted for GSK and Amgen.
Editor: C. Dean Buckner, MD, OncoEd, Inc.
Disclosure: Dr. Buckner has no relevant financial interests to disclose.
Interviewer: Kari Bohlke, ScD, OncoEd, Inc.
Disclosure: Dr. Bohlke has no relevant financial interests to disclose.
Investigational and/or off-label use of commercial products and devices
CEC requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.
The presentations in this CME activity might include discussion of investigational and/or unlabeled use of drugs. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.
This presentation discusses the investigational use of romiplostim, lenalidomide, and azacitadine.
Privacy and Confidentiality
OncoEd is committed to respecting your privacy. We've structured our web site so that you can visit OncoEd on the web without identifying yourself or revealing any personal information. If you choose to provide us personally identifiable information, you can be assured that it will only be used to support your relationship with OncoEd.
On some OncoEd web pages, you can make requests, and register to receive materials. The types of personal information collected at these pages are name and contact information. In order to tailor our subsequent communications to you and continuously improve our products and services, we may also ask you to voluntarily provide us with information regarding your experience with cancer, personal or professional interests, demographics and contact preferences.
OncoEd is committed to ensuring the security of your information. To prevent unauthorized access, maintain data accuracy, and ensure the appropriate use of information, we have put in place appropriate physical, electronic, and managerial procedures to safeguard and secure the information we collect online.
OncoEd has links to many other sites and cannot ensure the privacy or security of information you provide to the linked site.
If you have comments or questions about our privacy policy, please send them to this email address: mail@onco-ed.com.
Disclaimer
Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC.
I have read the required CME information.
Yes: Click Here to Launch the Activity
No: Click Here to Return to the Homepage
Patient Home
